Navigation Links
WuXi PharmaTech Announces Third-Quarter 2010 Results
Date:11/9/2010

d for our broad-based and integrated drug discovery and development services. Growth in Manufacturing Services net revenues reflected higher demand for pharmaceutical advanced intermediates and active ingredients.

Third-quarter 2010 GAAP gross profit increased 4% year over year to $29.8 million, mainly due to increased revenues, partially offset by increased expenses, including depreciation expense, relating to the large-scale manufacturing facility in Jinshan, the toxicology facility in Suzhou, and new pharmacology/DMPK/chemistry laboratories in Shanghai. Laboratory Services gross profit increased 4% year over year to $28.6 million and Manufacturing Services gross profit was essentially unchanged year over year at $1.2 million. In addition, third-quarter 2010 GAAP gross profit was reduced by $3.1 million in transaction-related bonuses paid to scientist employees after the termination of the Charles River transaction.  These bonuses rewarded our employees' dedication to serving customers during the pendency of the previously proposed transaction.  Third-quarter 2010 GAAP gross margin declined year over year to 35.6% from 41.1%, mainly due to these bonuses (3.7 percentage-point impact) and the increase in depreciation and other operating expenses of the large-scale manufacturing and toxicology facilities and the new pharmacology/DMPK/chemistry laboratories. The company expects the full-year 2010 GAAP gross margin to decline about 2 percentage points.

Third-quarter 2010 GAAP operating income increased 31% year over year to $19.2 million, mainly due to strong revenue growth and lower general and administrative expenses. Of the $30 million termination fee that we received from Charles River, $5 million was used to offset the merger-related costs in general and administrative expenses ($2.9 million was incurred and recorded in second-quarter 2010 and $2.0 million was incurred and recorded in third-quarter 2010).  The remaining $25 million of
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
2. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
3. Professor Steven V. Ley Speaks at WuXi PharmaTech
4. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
5. WuXi PharmaTech Announces Second-Quarter 2010 Results
6. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
7. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
8. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
9. WuXi PharmaTech Announces First-Quarter 2010 Results
10. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
11. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... of bortezomib-relapsed patient population demonstrates 55% overall response ... 26 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... an ongoing Phase 1/2 study of KRX-0401 (perifosine) ... with relapsed/refractory multiple myeloma. The data, which was ...
... ExonHit Therapeutics,(Alternext: ALEHT) is pleased to announce that clinical ... is progressing well. Patient,enrolment for the Phase IIa trial ... , "The successful completion of ... in the development of EHT 0202, and,provides a clear ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 4ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... August 2014: Transvenous lead extraction (TLE) is clinically successful ... from the European Lead Extraction ConTRolled (ELECTRa) registry presented ... by Dr Maria Grazia Bongiorni, chair of the registry,s ... cardiac implantable electronic devices (CIED) implant procedures has grown ... of complications has increased and leads are often the ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... Approximately sixty-five state and local public health laboratories ... confirmatory testing of Human Influenza A H1N1 of Swine ... all swine flu specimens had to be sent to ... identifies specimens to the strain level.The rRT-PCR swine flu ...
... Approved Simponi is Expected to Achieve Strong ... a New Report from Decision ResourcesWALTHAM, Mass., ... the world,s leading research and advisory firms ... the availability of Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s ...
... Justice grant creates federal-state-local partnership to help fight ... A sweeping $1.1 million U.S. Justice Dept. grant ... prosecution agency to help combat domestic violence and ... State,s Attorney,s Appellate Prosecutor,s office has hired two ...
... promise in study , , THURSDAY, April 30 (HealthDay News) ... multiple sclerosis (MS) drug may give patients more relief ... a new study. , In the study, which included ... selected to receive the steroid drug methylprednisolone in three ...
... After surgery to remove the head of the pancreas, ... in a lower rate of pancreatic fistula, according to ... Center. The research was published in the Journal ... performed as a randomized trial the gold standard ...
... up 266%, , ... Winston-Salem, NC ... that it is expanding its corporate and satellite offices to ... system, VerteLoc™. , , , , ,"We are essentially doubling ...
Cached Medicine News:Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: